Virus specific antibody - based remedies for the urgent prevention and treatment of Ebola virus disease

Abstract

The Ebola virus (member of Ebolavirus genus Filoviridae family) is the etiologic agent of extremely hazard human disease with high mortality rates (up to 90%). The most important components of spectrum of therapeutics for special prophylactic and current of disease, caused by Ebola virus, are prepares, based on virus specific antibodies (convalescent’s plasma, geterologic immunoglobulins, monoclonal antibodies. The use of different class therapeutics, based on virus specific antibodies, the possible improvements of its composition and strategy of its application for special prophylactic and current of disease, caused by Ebola virus, are considered in this review.

virusMED: an atlas of hotspots of viral proteins

“…The primary prophylactic agents are vaccines that can imitate viruses and stimulate an immune response to provide protection from viral infections (Vetter et al, 2018). The currently used types of vaccines mainly include chemically inactivated viruses, attenuated viruses (Sizikova et al, 2019), recombinant protein antigens (Mascola & Fauci, 2020), replication-defective viruses, virus-like particles (Fuenmayor et al, 2017) and nucleic acid-vectored vaccines (Lee, Arun Kumar et al, 2018;Sandbrink & Shattock, 2020). However, traditional vaccines are often futile against viruses that mutate frequently, such as HIV and influenza (Oscherwitz, 2016).…”